Serial Number
97882540
Owner
VeriSIM Life Inc.Attorney
Norm J. RichFirst Use Date
Sep 30, 2022
Filing Date
Apr 11, 2023
TRANSLATIONAL INDEX Trademark
Serial Number: 97882540 • Registration: 7504463
Trademark Classes
Owner Contact Info
1 Sansome Street, Suite 3500
San Francisco, CA 94104
Entity Type: 03
Legal Representation
Trademark Details
Filing Date
April 11, 2023
Registration Date
September 10, 2024
First Use Anywhere
September 30, 2022
First Use in Commerce
September 30, 2022
Goods & Services
Software as a service (SAAS) services featuring software for modeling, rating, scoring and reporting on the conducting of simulations and predictions of properties of drugs or chemicals or vaccines including absorption, release rate, bioavailability, pharmacokinetics and pharmacodynamics, safety, toxicology, and efficacy profiles, routes of administration, and dose optimization; Software as a service (SAAS) services featuring software that allows for the simulation, prediction, rating, scoring, and reporting of drug-to-drug interactions; Software as a service (SAAS) services featuring software for the simulation, prediction, rating, scoring, and reporting of drug or vaccines or chemical effects on animals and virtual animal or patient populations; Software as a service (SAAS) services featuring software which allows researchers to adjust pharmacodynamic models to observed data and to then use the resulting fitted models to simulate, predict, rate, score, and report on pharmacodynamic changes due to changes in routes of administration, dose, dosage form, and dosing regimen of a drug or chemical or vaccine; Software as a service (SAAS) services featuring software which allow for the prediction, rating, scoring, and reporting of absorption and systemic distribution/elimination for large molecules; Software as a service (SAAS) services featuring software that incorporates artificial intelligence and machine learning to simulate, predict, rate, score, and report on the clinical efficacy of new drugs or chemicals or or vaccines before human trials and accelerate pharmaceutical drug or vaccine development and regulatory approval